with 1251-labeled digoxin kits from five different manufacturers. Values obtained for apparent digoxin were either negligible or not sufficiently great to be clinically significant, regardless of kit methodology or manufacturer.
Addftlonal Keyphrase: '*It" methods Serum digoxin assay is being requested more and more frequently.
Reports indicate that chances of digitalis toxicity are considerably increased when digoxin concentrations in blood are not monitored to see how closely the quantity in blood after therapeutic dosage approaches a toxic concentration (1, 2) . Other uses include assistance in diagnosis of toxicity and as an indication that a patient may be omitting medication.
As is the case for most laboratory tests, results must be interpreted in the context of the clinical find- A few reports (3, 6) and information in digoxin kits from several manufacturers (7-9) indicate that spironolactone and prednisone display the greatest potential for cross-reactivity among medications thus far investigated.
Phillips (4) and Zeegers et al. (6) confirmed that these two drugs may in fact produce laboratory error in digoxin 
Materials and Methods
Ten patients were selected who were receiving oral spironolactone (Aldactone or Aldactazide, G. D. Searle and Co.), 25 mg twice a day. I also selected the following patients on oral prednisone: 10 who were receiving 10 mg three or four times a day, one who was receiving 15 mg of prednisone once a day, one receiving 20 mg once a day, two receiving 25 mg twice a day, and one receiving 50 mg twice a day. Most of these patients had never received digitalis compounds, and none had taken digitalis for at least three weeks. Specimens were drawn 2 h after the last therapeutic dose, on the assumption that absorption would then be maximum.1 Each patient's serum specimen was assayed by 1-125 kits from each of the following five manufacturers: Clinical Assays ("Gammacoat"; Clinical Assays, Inc., Cambridge, Mass. 02142); Corning ("Immunophase";
Corning Co., Medfield, Mass. 02052); Kallestad ("Quantitope," ately were frozen. In our laboratory, we used semiautomatic pipets for all pipetting and a Searle (Nuclear-Chicago) Model 4222 automatic well counter for counting radioactivity. All pipets had previously been checked for reproducibility by the isotope dilution technique; the well counter was checked for efficiency by the chi-square test.
Results Tables 1 and 2 values obtained were zero or so low as to be clinically insignificant. Values of 0.4 ag/liter or more were obtained from at least one kit in five of 10 patients taking spironolactone. However, this occurred in only one or two of the five kits used to test each specimen, with at least two of the remaining three kits yielding zero values. In only one instance was a value as high as 0.7 pg/liter obtained. In patients taking 10-mg doses of prednisone, even less reactivity was observed, with only one instance in which a value of 0.5 ug/liter was found. In more limited data on patients taking more than 10-mg doses of prednisone, slightly more reactivity was obtained in that three of five such patients had at least one kit assay value as high as 0.4 gig/liter (contrasted to two of 10 patients taking 10-mg doses). However, this difference is probably not significant, because in each case only one of the five kits produced the higher result. In no case were higher values obtained in patients receiving higher prednisone doses.
Discussion
These results indicate that spironolactone or prednisone therapy should not interfere significantly with digoxin assay. This is contrary to the experience of Zeegers et al. (6), who reported that four patients receiving 25 mg spironolactone daily and no digoxin produced false apparent digoxin values of 0.7, 1.7, 1.8, and 4.0 Mg/liter. BurroughsWellcome tritiated (3H) kit was probably used, which admittedly is not included in this study. In addition, their work was performed at least two years before the current investigation, during which time significant changes may have been made in antibody specificity.
It is very common for digitalis to be administered to patients on spironolactone, and spironolactone is prescribed with a significant degree of frequency in patients taking digitalis. This fact is the basis for undertaking the present investigation. It also provides an example of certain problems in studies of this type. Several patients initially had significantly elevated and presumably false results for digoxin assay, as assayed with any of the kits, some between 2 and 3 Mg/liter. On retrospective inquiry, all of these patients had to be excluded because their values probably represented true digoxin. In two instances, digoxin therapy was begun during the interval between the time a blood sample was ordered and actual specimen collection next day. In the other cases, digoxin had been administered before admission, but was not mentioned in the physician's admitting note.
Although oral prednisone therapy does not seem to interfere with digoxin assay, I was not able to evaluate the effect of intravenous hydrocortisone, because all patients undergoing this type of therapy during the study were also receiving digitalis. 
